Compare · NVO vs VYNE
NVO vs VYNE
Side-by-side comparison of Novo Nordisk A/S (NVO) and VYNE Therapeutics Inc. (VYNE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and VYNE operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $220.35B, about 7282.1x VYNE ($30.3M).
- Over the past year, NVO is down 34.2% and VYNE is down 55.6% - NVO leads by 21.3 points.
- NVO has hit the wire 5 times in the past 4 weeks while VYNE has been quiet.
- NVO has more recent analyst coverage (25 ratings vs 3 for VYNE).
- Company
- Novo Nordisk A/S
- VYNE Therapeutics Inc.
- Price
- $41.18+6.93%
- $0.65+0.09%
- Market cap
- $220.35B
- $30.3M
- 1M return
- +13.32%
- +5.43%
- 1Y return
- -34.24%
- -55.58%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2018
- News (4w)
- 5
- 0
- Recent ratings
- 25
- 3
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
VYNE Therapeutics Inc.
VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing and commercializing various therapeutics for dermatology. The company offers AMZEEQ, a topical minocycline used for the treatment of inflammatory lesions of non-nodular moderate-to-severe acne vulgaris in patients 9 years of age and older; and ZILXI for the treatment of inflammation lesions of papulopustular rosacea in adults. It is also developing FCD105, a topical combination foam that has completed Phase II clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in preclinical trial for the treatment of mild-to-moderate atopic dermatitis. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.
Latest NVO
- The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Wolfe Research initiated coverage on Novo Nordisk A/S
Latest VYNE
- SEC Form 4 filed by Zeronda Tyler
- SEC Form 4 filed by Stuart Iain
- SEC Form 4 filed by Harsch Mutya
- SEC Form 4 filed by Domzalski David
- SEC Form S-4 filed by VYNE Therapeutics Inc.
- SEC Form 8-K filed by VYNE Therapeutics Inc.
- SEC Form 10-K filed by VYNE Therapeutics Inc.
- SEC Form 425 filed by VYNE Therapeutics Inc.
- VYNE Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- PRESIDENT AND CEO Domzalski David covered exercise/tax liability with 12,684 shares, decreasing direct ownership by 3% to 416,208 units (SEC Form 4)